“Dynavax provided Phase 1b/2 updates on TLR9 agonist, SD-101 in combination with Keytruda, for head and neck squamous cell carcinoma (HNSCC) and metastatic melanoma at AACR.”,” the firm’s analyst commented.
A number of other equities analysts have also recently weighed in on XRAY. Credit Suisse Group cut shares of Dentsply Sirona to a hold rating and set a $73.00 price target on the stock. in a research report on Friday, January 5th. Zacks Investment Research cut shares of Dentsply Sirona from a hold rating to a sell rating in a research report on Monday, January 8th. HC Wainwright reissued a hold rating and set a $68.00 price target on shares of Dentsply Sirona in a research report on Thursday, January 18th. BidaskClub cut shares of Dentsply Sirona from a hold rating to a sell rating in a research report on Tuesday, January 23rd. Finally, Barrington Research reissued an outperform rating and set a $70.00 price target (down from $73.00) on shares of Dentsply Sirona in a research report on Monday, March 5th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the stock. Dentsply Sirona presently has an average rating of Hold and a consensus price target of $67.36.
Dentsply Sirona (NASDAQ:XRAY) last released its earnings results on Thursday, March 1st. The medical instruments supplier reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.01. Dentsply Sirona had a negative net margin of 39.39% and a positive return on equity of 8.35%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the business earned $0.67 EPS. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. equities analysts expect that Dentsply Sirona will post 2.72 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, April 13th. Investors of record on Thursday, March 29th were given a $0.0875 dividend. The ex-dividend date was Wednesday, March 28th. This represents a $0.35 annualized dividend and a yield of 0.70%. Dentsply Sirona’s dividend payout ratio is currently 13.16%.
Institutional investors and hedge funds have recently bought and sold shares of the stock. NuWave Investment Management LLC bought a new stake in Dentsply Sirona in the 4th quarter valued at $121,000. Focused Wealth Management Inc lifted its position in Dentsply Sirona by 79.2% in the 4th quarter. Focused Wealth Management Inc now owns 2,600 shares of the medical instruments supplier’s stock valued at $171,000 after acquiring an additional 1,149 shares in the last quarter. Stock Yards Bank & Trust Co. bought a new stake in Dentsply Sirona in the 4th quarter valued at $203,000. Capital One National Association bought a new stake in Dentsply Sirona in the 4th quarter valued at $204,000. Finally, Boston Common Asset Management LLC bought a new stake in Dentsply Sirona in the 4th quarter valued at $212,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.
About Dentsply Sirona
DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Receive News & Ratings for Dentsply Sirona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dentsply Sirona and related companies with MarketBeat.com's FREE daily email newsletter.